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In [Table 2](#pone.0217670.t001){ref-type="table"}, Prothionamide was mistakenly abbreviated "PRS" instead of "PRO" in the second column, "Screening Test". Please see the corrected [Table 2](#pone.0217670.t001){ref-type="table"} here.
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###### Screening of combinatorial drugs in macrophage model of *M*. *tuberculosis* infection.
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  ------------------------------------------------------------------------------------------------------------------------------------------
                                                        Screening test   Iteration \#1   Iteration\   Iteration\   Iteration\   Iteration\
                                                                                         \#2          \#3A         \#3B         \#3C
  ----------------------------------------------------- ---------------- --------------- ------------ ------------ ------------ ------------
  Effect levels[^a^](#t001fn001){ref-type="table-fn"}   2                3               3            5            5            3

  Test runs[^b^](#t001fn002){ref-type="table-fn"}       150              102             155          75           75           82

  Drugs[^c^](#t001fn003){ref-type="table-fn"}           AC               AC              AC           AC           AC           AC

  BDQ                                                   BDQ              BDQ             BDQ          BDQ          BDQ          

  CFZ                                                   CFZ              CFZ             CFZ          CFZ          CFZ          

  DLM                                                   DLM              DLM             DLM          DLM          DLM          

  RIF                                                   RIF              RIF             RIF          RIF          RIF          

  SQ109                                                 SQ109            SQ109           SQ109        SQ109        SQ109        

  PA824                                                 PA824            PA824           PA824                     PA824        

  PZA                                                   PZA              PZA             PZA                                    

  EMB                                                   EMB              EMB                                                    

  PAS                                                   PAS                                                                     

  PRO                                                   PRO                                                                     

  CYS                                                                                                                           

  INH                                                                                                                           

  LZD                                                                                                                           

  MXF                                                                                                                           
  ------------------------------------------------------------------------------------------------------------------------------------------

^a^Screening test was conducted at individual drug concentration that yielded 0% or 10% of the maximal inhibition to the IPTG-induced green fluorescence signal. Iteration \#1 was conducted at individual drug concentration that gave 0% or 10% of the maximal inhibition level and one-half of the concentration that gave 10% of the maximal inhibition level. Iteration \#2 was done at 0% or 15% effect levels and one-half of the concentration that gave 15% of the maximal inhibition level. Iterations \#3A and 3B were conducted at 0% or 20% effect level and two-thirds, one-half or one-fourth of the concentration that gave 20% of the maximal inhibition level. Iteration \#3C was conducted at 0% or 15% effect levels and one-half of the concentration that gave 15% of the maximal inhibition level.

^b^Number of combinatorial drug test runs in each experiment.

^c^List of drugs tested at screening and each stage of iterations.

On the right side of [Fig 1](#pone.0217670.g001){ref-type="fig"}, Group O was mistakenly omitted from the alphabetical list of drug regimen definitions. Please see the corrected [Fig 1](#pone.0217670.g001){ref-type="fig"} here.

![*In vivo* short-term efficacy screen of experimental regimens identified in macrophage studies using the PRS platform.\
*M*. *tuberculosis* infected mice were sham treated (Treatment Group A) or treated with the Standard Regimen (Treatment Group B), PRS Regimen II (Treatment Group C) or one of the top 4-drug combinations (Treatment Groups D-Q) identified from macrophage screening using the PRS platform starting from a pool of 15 TB drugs 5 days per week for 3 weeks. Three days after the last treatment, mice were euthanized to determine bacterial number in the lung. Standard Regimen is comprised of INH, RIF, EMB and PZA at 25, 10, 100 and 150 mg/kg, respectively. PRS Regimen II is comprised of CFZ, BDQ, PZA and EMB at 25, 30, 450 and 100 mg/kg, respectively. Drug doses used in the top 4-drug experimental regimens are as follows: 200--50 mg/kg for AC, 30 mg/kg for BDQ, 25 mg/kg for CFZ, 2.5 mg/kg for DLM, 100 mg/kg for PA824, 450 mg/kg for PZA, 10 mg/kg for RPT and 25 mg/kg for SQ109.](pone.0217670.g001){#pone.0217670.g001}
